SCHEMBL5875642

SCHEMBL5875642

CCCC(NC(=O)C(c1cc(F)cc(F)c1)C(C)(C)O)C(=O)Nc1nccs1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSPA5 P11021 3/20 0.54
PSEN1 P49768 13/20 0.51
PSEN2 P49810 13/20 0.51
APH1B Q8WW43 13/20 0.51
NCSTN Q92542 13/20 0.51
APH1A Q96BI3 13/20 0.51
PSENEN Q9NZ42 13/20 0.51
ALDH1A1 P00352 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
FFAR2 O15552 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8258676 0.92 HSPA5 (0.52) HSPA5PSEN1PSEN2APH1BNCSTN
SCHEMBL5875775 0.81 PSEN1 (0.68) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6820524 0.78 HSPA5 (0.61) HSPA5ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL18939226 0.71 FFAR2 (0.78) HSPA5ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL8260271 0.69 PSEN1 (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8258706 0.69 PSEN1 (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8258549 0.69 PSEN1 (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8252654 0.68 PSEN1 (0.73) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5875678 0.68 CYP1A2 (0.62) HSPA5ALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL8260364 0.67 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP HSPA5 1208/4885PSEN1 5/4885PSEN2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.